8-K: Maximus Reports Strong Fiscal Year 2024 Results and Issues 2025 Guidance

Maximus reported an 8.2% increase in full-year revenue to $5.31 billion and provided fiscal year 2025 guidance.

Summary

• Maximus announced its financial results for the fourth quarter and full fiscal year 2024, ending September 30, 2024.
• Full-year revenue increased by 8.2% to $5.31 billion, up from $4.90 billion in the prior year, with organic growth at 8.8%.
• Fourth-quarter revenue grew by 4.4% to $1.32 billion, or 4.7% on an organic basis.
• Full-year diluted earnings per share were $4.99, and adjusted diluted earnings per share were $6.11.
• Fourth-quarter diluted earnings per share were $1.19, and adjusted diluted earnings per share were $1.46.
• Cash flows from operating activities for the full year totaled $515 million, and free cash flow was $401 million.
• The company's leverage ratio was 1.4x at September 30, 2024, down from 2.2x in the prior year.
• A quarterly cash dividend of $0.30 per share is payable on November 30, 2024.
• Fiscal year 2025 revenue is projected to be between $5.275 billion and $5.425 billion.
• The adjusted EBITDA margin for fiscal year 2025 is expected to be approximately 11.0%.
• Adjusted diluted earnings per share for fiscal year 2025 are projected to range between $5.70 and $6.00.
• Free cash flow for fiscal year 2025 is expected to be between $345 million and $375 million.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results and optimistic guidance for the next fiscal year. The company's performance is solid, and the management commentary is upbeat, leading to a high sentiment score.

Positives

• Maximus achieved strong revenue growth for the full fiscal year, with an 8.2% increase.
• The company's organic growth was a robust 8.8%, indicating strong performance in core operations.
• Both diluted and adjusted diluted earnings per share showed significant improvement compared to the prior year.
• Cash flow from operations and free cash flow increased substantially year-over-year.
• The company successfully reduced its leverage ratio to 1.4x, demonstrating improved financial health.
• The company has provided positive guidance for fiscal year 2025, indicating continued growth and profitability.
• The U.S. Federal Services segment saw a 13.9% revenue increase, driven by clinical program growth.
• The U.S. Services segment also experienced a 5.5% revenue increase, driven by Medicaid-related activities.
• The Outside the U.S. segment returned to profitability, with an operating profit of $7.7 million.

Negatives

• The Outside the U.S. segment experienced a 4.6% revenue decrease for the full year.
• The book-to-bill ratio was 0.4x, reflecting a lower-than-normal period of rebid activity.
• Backlog decreased to $16.2 billion from $20.7 billion in the prior year, due to contract changes.
• The company anticipates a decrease in free cash flow for fiscal year 2025 compared to fiscal year 2024.

Risks

• The company's future performance is subject to risks and uncertainties, including those related to government contracts and market conditions.
• The upcoming U.S. Presidential transition could impact the company's business.
• The lower book-to-bill ratio indicates potential challenges in securing new contracts.
• The decrease in backlog could affect future revenue streams.
• The company's reliance on government contracts exposes it to changes in government spending and priorities.

Future Outlook

Maximus has provided fiscal year 2025 guidance, projecting revenue between $5.275 billion and $5.425 billion, an adjusted EBITDA margin of approximately 11.0%, and adjusted diluted earnings per share between $5.70 and $6.00. Free cash flow is expected to range between $345 million and $375 million.

Management Comments

• Bruce Caswell, President and Chief Executive Officer, stated that the company is proud of the team's performance and that the results demonstrate a healthy core business.
• Caswell also mentioned that the company is well-positioned to advise, adapt, and rapidly implement new priorities due to its role as a partner to government.

Industry Context

Maximus operates in the government services sector, which is influenced by government spending, policy changes, and political transitions. The company's performance is tied to the demand for its services in areas such as healthcare, human services, and technology solutions. The company's focus on clinical programs and Medicaid-related activities aligns with current trends in government spending.

Comparison to Industry Standards

• Maximus' revenue growth of 8.2% is solid compared to other government service providers, such as Cognizant (CTSH) which has seen revenue growth in the low single digits in recent quarters, and Accenture (ACN) which has seen growth in the mid single digits.
• The adjusted EBITDA margin of 11.6% is competitive with industry peers, although some companies like Booz Allen Hamilton (BAH) may have higher margins due to different business models.
• The leverage ratio of 1.4x is conservative compared to some peers, indicating a strong balance sheet.
• The book-to-bill ratio of 0.4x is lower than some competitors, such as Leidos (LDOS), which typically have a book-to-bill ratio closer to 1.0x, indicating a potential need for increased contract wins in the future.

Stakeholder Impact

• Shareholders will benefit from the increased earnings per share and the quarterly cash dividend.
• Employees may see increased job security and potential for career growth due to the company's strong performance.
• Customers, primarily government agencies, will continue to receive services from a financially stable and growing company.
• Suppliers and creditors will benefit from the company's improved financial health and ability to meet its obligations.

Next Steps

• Maximus will host a conference call on November 21, 2024, to discuss the financial results.
• The company will file its Annual Report on Form 10-K with the SEC shortly.

Key Dates

Keywords

Maximus, government services, financial results, revenue, earnings per share, EBITDA, cash flow, fiscal year 2024, fiscal year 2025, guidance, Medicaid, government contracts